The anthracyclines: will we ever find a better doxorubic

Seminars in Oncology
19, 670-86

Citation Report

#	Article	IF	Citations
1	Design and synthesis of anthracycline and distamycin derivatives as new, sequence-specific, DNA-binding pharmacological agents. Gene, 1994, 149, 57-61.	1.0	9
2	Formation of adriamycin-DNA adductsin vitro. Nucleic Acids Research, 1994, 22, 2296-2303.	6.5	55
3	In vitro activity of taxol and taxotere in comparison with doxorubicin and cisplatin on primary cell cultures of human breast cancers. Breast Cancer Research and Treatment, 1995, 34, 63-69.	1.1	24
4	In vitro anthracycline cross-resistance pattern in childhood acute lymphoblastic leukaemia. British Journal of Cancer, 1995, 71, 1188-1193.	2.9	20
5	Î²-Glucuronyl carbamate based pro-moieties designed for prodrugs in ADEPT. Tetrahedron Letters, 1995, 36, 1701-1704.	0.7	26
6	Anticancer drugs: an underestimated risk or an underutilised resource in mutagenesis?. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1995, 331, 1-26.	0.4	33
7	Molecular structure of the halogenated anti-cancer drug iododoxorubicin complexed with d(TGTACA) and d(CGATCG). Nucleic Acids Research, 1995, 23, 4488-4494.	6.5	20
8	Stability of adriamycin-induced DNA adducts and interstrand crosslinks. Nucleic Acids Research, 1995, 23, 42-50.	6.5	55
10	A Risk-Benefit Assessment of Anthracycline Antibiotics in Antineoplastic Therapy. Drug Safety, 1996, 15, 406-429.	1.4	31
11	High yield conversion of doxorubicin to 2-pyrrolinodoxorubicin, an analog 500-1000 times more potent: structure-activity relationship of daunosamine-modified derivatives of doxorubicin.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 2464-2469.	3.3	85
12	Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 7269-7273.	3.3	195
13	Inhibition of anthracycline semiquinone formation by ICRF-187 (Dexrazoxane) in cells. Free Radical Biology and Medicine, 1996, 20, 905-914.	1.3	23
14	Pharmacology of N,N-di(n-butyl)adriamycin-14-valerate in the rat. Cancer Chemotherapy and Pharmacology, 1996, 37, 472-478.	1.1	3
15	Semisynthesis of a highly functionalized daunorubicin derivative. Tetrahedron Letters, 1996, 37, 1123-1124.	0.7	2
16	Serniauinonel Free Radical Formation by Daunorubicin Aglycone Incorporated into the Cellulir Membranes of Intact Chinese Hamster Ovary Cells. Free Radical Research, 1996, 24, 9-18.	1.5	14
17	Doxorubicin Disaccharide Analogue: Apoptosis-Related Improvement of Efficacy In Vivo. Journal of the National Cancer Institute, 1997, 89, 1217-1223.	3.0	58
18	Anthracycline maintenance therapy limited by risk of cardiotoxicity. Drugs and Therapy Perspectives, 1997, 10, 13-16.	0.3	0
19	Anthrazykline in der Krebstherapie. Drugs, 1997, 54, 1-7.	4.9	448

#	Article	IF	Citations
20	Intratibial injection of an anti-doxorubicin monoclonal antibody prevents drug-induced myelotoxicity in mice. British Journal of Cancer, 1997, 75, 656-659.	2.9	7
21	Production of the antitumor drug epirubicin (4â€²-epidoxorubicin) and its precursor by a genetically engineered strain of Streptomyces peucetius. Nature Biotechnology, 1998, 16, 69-74.	9.4	147
22	Upregulation of P-glycoprotein in rat hepatoma ïÂ° cells: Implications for drugâ€“DNA interactions. Journal of Cellular Biochemistry, 1998, 69, 463-469.	1.2	8
23	Simultaneous determination of epirubicin, doxorubicin and their principal metabolites in human plasma by high-performance liquid chromatography and electrochemical detection. Biomedical Applications, 1998, 707, 219-225.	1.7	63
24	The antitumour activity of the prodrug N-l-leucyl-doxorubicin and its parent compound doxorubicin in human tumour xenografts. European Journal of Cancer, 1998, 34, 1602-1606.	1.3	30
25	Doxorubicin-Induced Cardiomyopathy. New England Journal of Medicine, 1998, 339, 900-905.	13.9	1,617
26	Characterization of covalent Adriamycin-DNA adducts. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 11561-11565.	3.3	147
27	Identification and hydropathic characterization of structural features affecting sequence specificity for doxorubicin intercalation into DNA double-stranded polynucleotides. Nucleic Acids Research, 1998, 26, 4721-4732.	6.5	64
28	Role of iron in anthracycline cardiotoxicity: new tunes for an old song?. FASEB Journal, 1999, 13, 199-212.	0.2	183
29	Increasing dose of Continuous Infusion Ifosfamide and Fixed dose of Bolus Epirubicin in Soft Tissue Sarcomas. A Study of the Italian Group on Rare Tumors. Tumori, 1999, 85, 229-233.	0.6	13
30	A chemically labeled cytotoxic agent: Two-photon fluorophore for optical tracking of cellular pathway in chemotherapy. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 11081-11084.	3.3	96
31	Barminomycin forms GC-specific adducts and virtual interstrand crosslinks with DNA. Nucleic Acids Research, 1999, 27, 1781-1787.	6.5	11
32	Anthraquinone-induced cell injury: acute toxicity of carminomycin, epirubicin, idarubicin and mitoxantrone in isolated cardiomyocytes. Toxicology, 1999, 135, 11-20.	2.0	19
33	Configurational requirements of the sugar moiety for the pharmacological activity of anthracycline disaccharides. Biochemical Pharmacology, 1999, 57, 1133-1139.	2.0	34
34	Hybrid compounds derived from the combination of anthracycline and actinorhodin biosynthetic pathways. Journal of the Chemical Society Perkin Transactions II, 1999, , 1649-1652.	0.9	8
35	Adriamycin-induced heart failure: mechanism and modulation. Molecular and Cellular Biochemistry, 2000, 207, 77-86.	1.4	361
36	Prodrugs of natural anthracycleves suited for antibody directed enzyme prodrug therapy (ADEPT) and prodrug monotherapy (PMT). Studies in Natural Products Chemistry, 2000, 21, 157-180.	0.8	2
37	The cardioprotective effect of the iron chelator dexrazoxane (ICRF-187) on anthracycline-mediated cardiotoxicity. Redox Report, 2000, 5, 317-324.	1.4	24

#	Article	IF	Citations
38	Interstrand cross-linking by Adriamycin in nuclear and mitochondrial DNA of MCF-7 cells. Nucleic Acids Research, 2000, 28, 1019-1025.	6.5	47
39	Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: Implications for the design of preclinical studies. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 829-834.	3.3	83
40	The effects of daunomycin antibiotic on histone H1: thermal denaturation and fluorescence spectroscopy studies. International Journal of Biological Macromolecules, 2000, 28, 75-79.	3.6	11
41	Hybrid Anthracyclines from a Genetically EngineeredStreptomycesgalilaeusMutant. Journal of Organic Chemistry, 2000, 65, 2851-2855.	1.7	16
42	Anthracycline drug targeting: cytoplasmic versus nuclear â€“ a fork in the road. Drug Resistance Updates, 2001, 4, 169-177.	6.5	67
43	Tissue distribution, antitumour activity and in vivo apoptosis induction by MEN10755 in nude mice. European Journal of Cancer, 2001, 37, 431-437.	1.3	15
44	Molecular Mechanisms of Cardiac Hypertrophy Induced by Toxicants. Cardiovascular Toxicology, 2001, 1, 267-284.	1.1	37
45	A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer. British Journal of Cancer, 2001, 84, 550-557.	2.9	66
46	Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue. British Journal of Pharmacology, 2001, 134, 1271-1278.	2.7	32
47	Role of the sugar moiety in the pharmacological activity of anthracyclines: development of a novel series of disaccharide analogs. Biochemical Pharmacology, 2001, 61, 933-938.	2.0	63
48	A comparative study of cellular and molecular pharmacology of doxorubicin and MEN 10755, a disaccharide analogue11Abbreviations: DOX, doxorubicin; DNA-SSB, single-strand breaks; and DNA-DSB, double-strand breaks.. Biochemical Pharmacology, 2001, 62, 63-70.	2.0	17
49	Barminomycin functions as a potent pre-activated analogue of Adriamycin. Chemico-Biological Interactions, 2001, 138, 137-153.	1.7	9
50	Recent Advances in the Systemic Management of Metastatic Breast Cancer. Journal of Pharmacy Practice, 2002, 15, 52-61.	0.5	2
51	Phase I study of MEN-10755, a new anthracycline in patients with solid tumours: a report from the European Organization for Research and Treatment of Cancer, Early Clinical Studies Group. Annals of Oncology, 2002, 13, 385-391.	0.6	17
52	Promoter-specific inhibition of transcription by daunorubicin in Saccharomyces cerevisiae. Biochemical Journal, 2002, 368, 131-136.	1.7	12
53	Minimising the Long-Term Adverse Effects of Childhood Leukaemia Therapy. Drug Safety, 2002, 25, 1057-1077.	1.4	21
54	Antitumor effects of the cytotoxic luteinizing hormoneâ€“releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice. American Journal of Obstetrics and Gynecology, 2002, 187, 528-537.	0.7	91
55	Anthracyclines potentiate activity against murine leukemias L1210 and P388 in vivo and in vitro. European Journal of Haematology, 2002, 68, 370-375.	1.1	17

#	Article	IF	Citations
56	Deferiprone protects against doxorubicin-induced myocyte cytotoxicity. Free Radical Biology and Medicine, 2002, 33, 266-275.	1.3	77
57	Effect of coenzyme Q10 on the disposition of doxorubicin in rats. European Journal of Drug Metabolism and Pharmacokinetics, 2002, 27, 185-192.	0.6	6
58	The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin. Free Radical Biology and Medicine, 2003, 35, 1469-1479.	1.3	102
59	Anthracycline secondary alcohol metabolite formation in human or rabbit heart: biochemical aspects and pharmacologic implications. Biochemical Pharmacology, 2003, 66, 989-998.	2.0	58
60	Pegylated Liposomal Doxorubicin in the Treatment of Breast Cancer. Clinical Breast Cancer, 2003, 4, 318-328.	1.1	101
61	Ifosfamide in the Adjuvant Therapy of Soft Tissue Sarcomas. Oncology, 2003, 65, 80-84.	0.9	173
62	Prevention of doxorubicin-induced damage to rat heart myocytes by arginine analog nitric oxide synthase inhibitors and their enantiomers. Nitric Oxide - Biology and Chemistry, 2003, 9, 211-216.	1.2	11
63	Telemetrically monitored arrhythmogenic effects of doxorubicin in a dog model of heart failure. Pathophysiology, 2003, 9, 241-248.	1.0	6
64	Induction of apoptosis by Paljin-Hangahmdan on human leukemia cells. Journal of Ethnopharmacology, 2003, 88, 79-83.	2.0	12
65	Modeling the Metabolism of Idarubicin to Idarubicinol in Rat Heart: Effect of Rutin and Phenobarbital. Drug Metabolism and Disposition, 2003, 31, 462-468.	1.7	16
66	Hydropathic analysis of the free energy differences in anthracycline antibiotic binding to DNA. Nucleic Acids Research, 2003, 31, 4410-4416.	6.5	24
67	A BRIEF HISTORY OF DRUGS: FROM PLANT EXTRACTS TO DNA TECHNOLOGY. , 2003, , 3-28.		1
69	Differential Toxicity of Anthracyclines on Cultured Endothelial Cells. Endothelium: Journal of Endothelial Cell Research, 2004, 11, 253-258.	1.7	26
70	N-hexanoyl-sphingomyelin potentiates in vitro doxorubicin cytotoxicity by enhancing its cellular influx. British Journal of Cancer, 2004, 90, 917-925.	2.9	43
71	Sequence selective binding of bis-daunorubicin WP631 to DNA. FEBS Journal, 2004, 271, 3556-3566.	0.2	11
72	Synthesis of Anthracyclinone Precursor: 5,12â€Dihydroxyâ€1,3,4â€trihydronaphthaceneâ€2,6,11â€quinone. Synthetic Communications, 2004, 34, 3047-3059.	1.1	6
73	Development of an optimal sampling strategy for clinical pharmacokinetic studies of the novel anthracycline disaccharide analogue MEN-10755. Cancer Chemotherapy and Pharmacology, 2004, 54, 64-70.	1.1	3
74	Trace determination of anthracyclines in urine: a new high-performance liquid chromatography/tandem mass spectrometry method for assessing exposure of hospital personnel. Rapid Communications in Mass Spectrometry, 2004, 18, 2426-2436.	0.7	53

#	Article	IF	Citations
75	Distinctive regulation and function of PI 3K/Akt and MAPKs in doxorubicin-induced apoptosis of human lung adenocarcinoma cells. Journal of Cellular Biochemistry, 2004, 91, 621-632.	1.2	43
76	A new protocol for benzoannulation by double Claisen rearrangement and ring-closing metathesis reactions as key steps. Tetrahedron Letters, 2004, 45, 2585-2588.	0.7	58
77	Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity. Pharmacological Reviews, 2004, 56, 185-229.	7.1	3,060
78	Poncirus trifoliata fruit induces apoptosis in human promyelocytic leukemia cells. Clinica Chimica Acta, 2004, 340, 179-185.	0.5	44
79	Doxorubicin Cardiotoxicity and the Control of Iron Metabolism: Quinone-Dependent and Independent Mechanisms. Methods in Enzymology, 2004, 378, 340-361.	0.4	101
80	Concise synthesis and voltammetric studies of dielsiquinone, a cytotoxic azaanthraquinone. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 3609-3610.	1.0	9
81	Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. British Journal of Haematology, 2005, 131, 561-578.	1.2	381
82	Spectrophotometric investigation of the chemical compatibility of the anticancer drugs irinotecan-HCl and epirubicin-HCl in the same infusion solution. Cancer Chemotherapy and Pharmacology, 2005, 56, 529-534.	1.1	9
83	Antarth, a polyherbal preparation protects against the doxorubicin-induced toxicity without compromising its Antineoplastic activity. Phytotherapy Research, 2005, 19, 772-778.	2.8	14
84	Coformulated N-Octanoyl-glucosylceramide Improves Cellular Delivery and Cytotoxicity of Liposomal Doxorubicin. Journal of Pharmacology and Experimental Therapeutics, 2005, 315, 704-710.	1.3	31
85	Design and synthesis of novel sugar-oxasteroid-quinone hybrids. Organic and Biomolecular Chemistry, 2005, 3, 848.	1.5	52
86	Anthracycline-Induced Cardiotoxicity in Children with Cancer. Paediatric Drugs, 2005, 7, 67-76.	1.3	56
87	Induction of fetal haemoglobin expression in erythroid cells â€“ A model based on iron availability signalling. Medical Hypotheses, 2005, 65, 932-936.	0.8	4
88	A thermodynamic signature for drugâ€“DNA binding mode. Archives of Biochemistry and Biophysics, 2006, 453, 26-31.	1.4	368
89	p38 MAPK downregulates phosphorylation of Bad in doxorubicin-induced endothelial apoptosis. Biochemical and Biophysical Research Communications, 2006, 347, 781-790.	1.0	25
90	Alterations in myocardial energy metabolism induced by the anti-cancer drug doxorubicin. Comptes Rendus - Biologies, 2006, 329, 657-668.	0.1	78
91	Differential cardiotoxic/cardioprotective effects ofÂÎ²-adrenergic receptor subtypes inÂmyocytes andÂfibroblasts inÂdoxorubicin cardiomyopathy. Journal of Molecular and Cellular Cardiology, 2006, 40, 375-383.	0.9	34
92	New insights into doxorubicin-induced cardiotoxicity: The critical role of cellular energetics. Journal of Molecular and Cellular Cardiology, 2006, 41, 389-405.	0.9	298

#	Article	IF	Citations
93	Interaction of daunomycin antibiotic with human Î±1-acid glycoprotein: Spectroscopy and modeling. Journal of Molecular Structure, 2006, 788, 30-35.	1.8	1
94	Monitoring chemotherapy-induced cardiotoxicity: Role of cardiac nuclear imaging. Journal of Nuclear Cardiology, 2006, 13, 415-426.	1.4	54
95	Apoptosis and anthracycline cardiotoxicity. Molecular Cancer Therapeutics, 2006, 5, 197-199.	1.9	24
96	Identification of Genes Required for Protection from Doxorubicin by a Genome-Wide Screen in Saccharomyces cerevisiae. Cancer Research, 2007, 67, 11411-11418.	0.4	40
97	Synthesis of the Sugar Moieties. Topics in Current Chemistry, 2007, , 249-284.	4.0	3
98	Sabarubicin. Topics in Current Chemistry, 2007, 283, 171-189.	4.0	3
99	Activation of clinically used anthracyclines by the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate. Molecular Cancer Therapeutics, 2007, 6, 1450-1459.	1.9	17
100	Increased resistance of tumor cells to daunorubicin after transfection of cDNAs coding for anthracycline inactivating enzymes. Cancer Letters, 2007, 255, 49-56.	3.2	63
101	Acetylsalicylic acid exhibits anticlastogenic effects on cultured human lymphocytes exposed to doxorubicin. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2007, 626, 155-161.	0.9	15
102	Effect of farmorubicin both free and associated with poly(butylcyanoacrylate) nanoparticles on phagocytic and NK activity of peritoneal exudate cells from tumor-bearing mice. Journal of Drug Targeting, 2007, 15, 302-310.	2.1	5
103	Type II polyketide synthases: gaining a deeper insight into enzymatic teamwork. Natural Product Reports, 2007, 24, 162-190.	5.2	513
104	Molecular Mechanisms of Anthracycline Activity. Topics in Current Chemistry, 2007, 283, 1-19.	4.0	35
105	Synthesis andIn Vitro Cytotoxicity Evaluation of Novel Naphthindolizinedione Derivatives. Archiv Der Pharmazie, 2007, 340, 147-153.	2.1	13
106	Formation of Arenesvia Diallylarenes: Strategic Utilization of Suzukiâ€“Miyaura Cross-Coupling, Claisen Rearrangement and Ring-Closing Metathesis. Advanced Synthesis and Catalysis, 2007, 349, 1159-1172.	2.1	65
107	Evaluation of relative DNA binding affinities of anthrapyrazoles by electrospray ionization mass spectrometry. Journal of Mass Spectrometry, 2007, 42, 681-688.	0.7	20
108	Hollow chitosan-alginate multilayer microcapsules as drug delivery vehicle: doxorubicin loading and in vitro and in vivo studies. Nanomedicine: Nanotechnology, Biology, and Medicine, 2007, 3, 63-74.	1.7	213
109	In vivo and in vitro antitumor activity of doxorubicinâ€loaded magnetic fluids. Physica Status Solidi C: Current Topics in Solid State Physics, 2007, 4, 4345-4351.	0.8	8
110	Effect of Adriamycin on superoxide radical generation in isolated heart mitochondria. Biophysics (Russian Federation), 2007, 52, 582-586.	0.2	2

#	Article	IF	Citations
111	Doxorubicin-Induced Cardiomyopathy. Progress in Cardiovascular Diseases, 2007, 49, 330-352.	1.6	700
112	Anthracycline-induced phospholipase A2 inhibition. Cardiovascular Toxicology, 2007, 7, 86-91.	1.1	15
113	Effect of Terminalia arjuna extract on adriamycinâ€induced DNA damage. Phytotherapy Research, 2008, 22, 1188-1194.	2.8	14
114	Layered microcapsules for daunorubicin loading and release as well as in vitro and in vivo studies. Polymers for Advanced Technologies, 2008, 19, 36-46.	1.6	38
115	CEâ€LIF method for the separation of anthracyclines: Application to protein binding analysis in plasma using ultrafiltration. Journal of Separation Science, 2008, 31, 1828-1833.	1.3	27
116	First Total Synthesis of the Potent Anticancer Natural Product Dideoxypetrosynol A: Preparation of the â€œSkippedâ€•(Z)â€Enediyne Moiety by Oxidative Coupling of Homopropargylphosphonium Ylide. European Journal of Organic Chemistry, 2008, 2008, 4790-4795.	1.2	11
117	Reversible derivatization to enhance enzymatic synthesis: Chemoenzymatic synthesis of doxorubicinâ€14â€Oâ€esters. Biotechnology and Bioengineering, 2008, 101, 435-440.	1.7	5
118	Hyperbaric Oxygen Therapy Does Not Potentiate Doxorubicinâ€induced Cardiotoxicity in Rats. Basic and Clinical Pharmacology and Toxicology, 2008, 102, 287-292.	1.2	28
119	Drug-induced apoptosis in yeast. Biochimica Et Biophysica Acta - Molecular Cell Research, 2008, 1783, 1436-1448.	1.9	62
120	Effect of gamma irradiation on spleen cell function and cytotoxicity of doxorubicin. Chemico-Biological Interactions, 2008, 173, 205-214.	1.7	10
121	Flavonoids as inhibitors of human carbonyl reductase 1. Chemico-Biological Interactions, 2008, 174, 98-108.	1.7	30
122	Reduction of doxorubicin and oracin and induction of carbonyl reductase in human breast carcinoma MCF-7 cells. Chemico-Biological Interactions, 2008, 176, 9-18.	1.7	33
123	The Aldo-Keto Reductase Superfamily and its Role in Drug Metabolism and Detoxification. Drug Metabolism Reviews, 2008, 40, 553-624.	1.5	419
124	Vincristine attenuates doxorubicin cardiotoxicity. Biochemical and Biophysical Research Communications, 2008, 373, 555-560.	1.0	43
125	Methyl 3-Amino-2,3,6,-trideoxy-l-hexopyranosides in DFT Level Theory Conformational Studies. Journal of Physical Chemistry A, 2008, 112, 7072-7079.	1.1	8
126	A History of Drug Discovery. , 2008, , 1-62.		9
127	Cardioprotective Effects of Fullerenol C₆₀(Oh)₂₄ on a Single Dose Doxorubicin-induced Cardiotoxicity in Rats with Malignant Neoplasm. Technology in Cancer Research and Treatment, 2008, 7, 15-25.	0.8	56
128	Aldo-Keto Reductase 1C2 Fails to Metabolize Doxorubicin and Daunorubicin in Vitro. Drug Metabolism and Disposition, 2008, 36, 991-994.	1.7	15

#	Article	IF	Citations
129	Detection of Adriamycinâ€“DNA adducts by accelerator mass spectrometry at clinically relevant Adriamycin concentrations. Nucleic Acids Research, 2008, 36, e100.	6.5	70
130	Imaging of Cardiotoxicity. Molecular Imaging, 2008, 7, 7290.2008.00019.	0.7	1
131	CDK5RAP2 is required for spindle checkpoint function. Cell Cycle, 2009, 8, 1206-1216.	1.3	40
132	Development of Idarubicin and Doxorubicin Solid Lipid Nanoparticles to Overcome Pgp-Mediated Multiple Drug Resistance in Leukemia. Journal of Biomedical Nanotechnology, 2009, 5, 151-161.	0.5	148
133	Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway. Free Radical Biology and Medicine, 2009, 46, 1589-1597.	1.3	234
134	Cancer biomarker AKR1B10 and carbonyl metabolism. Chemico-Biological Interactions, 2009, 178, 134-137.	1.7	49
135	Total synthesis of polyyne natural products. Comptes Rendus Chimie, 2009, 12, 489-505.	0.2	47
136	N-acetylcysteine amide decreases oxidative stress but not cell death induced by doxorubicin in H9c2 cardiomyocytes. BMC Pharmacology, 2009, 9, 7.	0.4	45
137	Gamma irradiation reduces the immunological toxicity of doxorubicin, anticancer drug. Radiation Physics and Chemistry, 2009, 78, 425-428.	1.4	9
138	Physicochemical characterization and in vitro behavior of daunorubicin-loaded poly(butylcyanoacrylate) nanoparticles. Acta Biomaterialia, 2009, 5, 2109-2121.	4.1	46
139	Influence of substituent modifications on the binding of 2-amino-1,8-naphthyridines to cytosine opposite an AP site in DNA duplexes: thermodynamic characterization. Nucleic Acids Research, 2009, 37, 1411-1422.	6.5	78
140	Synthesis and DNA-binding affinity studies of glycosylated intercalators designed as functional mimics of the anthracycline antibiotics. Organic and Biomolecular Chemistry, 2009, 7, 3709.	1.5	36
141	A concise description of cardioprotective strategies in doxorubicin-induced cardiotoxicityThis article is one of a selection of papers published in a special issue celebrating the 125th anniversary of the Faculty of Medicine at the University of Manitoba.. Canadian Journal of Physiology and Pharmacology, 2009, 87, 756-763.	0.7	70
142	Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors. Retrovirology, 2009, 6, 25.	0.9	134
143	Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacological Reports, 2009, 61, 154-171.	1.5	633
144	Markers of oxidative status in a clinical model of oxidative assault: a pilot study in human blood following doxorubicin administration. Biomarkers, 2009, 14, 321-325.	0.9	18
145	Potentiation of the growth inhibition activity of 2-({4-[4-(acridin-9-ylamino)phenylthio]phenyl}(2-hydroxyethyl)amino)ethan-1-ol (CK0402) by Herceptin in SKBR-3 human breast cancer cells. Experimental and Therapeutic Medicine, 2010, 1, 513-518.	0.8	6
146	Doxorubicin translocation B7-H1 from the cell surface to the nucleus of breast cancer cells. Hematology/ Oncology and Stem Cell Therapy, 2010, 3, 163.	0.6	2

#	Article	IF	Citations
147	Alleviation of doxorubicinâ€induced toxicities by anthocyaninâ€rich bilberry (<i>Vaccinium myrtillus) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	2.6	17
148	Rational Design of Multifunctional Polymer Therapeutics for Cancer Theranostics. Israel Journal of Chemistry, 2010, 50, 185-203.	1.0	10
149	Synthesis and antibacterial activity of aminosugar-functionalized intercalating agents. Carbohydrate Research, 2010, 345, 10-22.	1.1	10
150	Conformational diversity of anthracycline anticancer antibiotics: A density functional theory calculation. Computational and Theoretical Chemistry, 2010, 951, 60-68.	1.5	22
151	Protective Effect of PACAP Against Doxorubicin-Induced Cell Death in Cardiomyocyte Culture. Journal of Molecular Neuroscience, 2010, 42, 419-427.	1.1	19
152	Inhibition of AMP-activated protein kinase pathway sensitizes human leukemia K562 cells to nontoxic concentration of doxorubicin. Molecular and Cellular Biochemistry, 2010, 340, 275-281.	1.4	9
153	Carbonyl reductase 1 as a novel target of (â^')-epigallocatechin gallate against hepatocellular carcinoma. Hepatology, 2010, 52, 703-714.	3.6	64
154	Measurement of intracellular accumulation of anthracyclines in cancerous cells by direct injection of cell lysate in MEKC/LIF detection. Electrophoresis, 2010, 31, 1396-1404.	1.3	18
155	Determination of the absolute configurations of synthetic daunorubicin analogues using vibrational circular dichroism spectroscopy and density functional theory. Chirality, 2010, 22, 734-743.	1.3	13
156	Investigation of microdialysis sampling calibration approaches for lipophilic analytes: Doxorubicin. Journal of Pharmaceutical and Biomedical Analysis, 2010, 53, 490-496.	1.4	18
157	Doxorubicin Cardiomyopathy. Cardiology, 2010, 115, 155-162.	0.6	836
158	Reduced in vivo high-energy phosphates precede Adriamycin-induced cardiac dysfunction. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 299, H332-H337.	1.5	44
159	Evaluation of the genotoxic and antigenotoxic effects after acute and subacute treatments with aÃ§ai pulp (Euterpe oleracea Mart.) on mice using the erythrocytes micronucleus test and the comet assay. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2010, 695, 22-28.	0.9	86
160	Cytotoxicity, intracellular distribution and uptake of doxorubicin and doxorubicin coupled to cell-penetrating peptides in different cell lines: A comparative study. Biochemical and Biophysical Research Communications, 2010, 391, 419-425.	1.0	99
161	Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule. Breast Cancer Research, 2010, 12, R48.	2.2	191
162	Selective toxicity of glycyrrhetinic acid against tumorigenic r/m HM-SFME-1 cells is potentially attributed to downregulation of glutathione. Biochimie, 2011, 93, 1172-1178.	1.3	12
163	NMR Insight into the Supramolecular Structure of Daunorubicin Loaded Polymer Nanoparticles. Journal of Physical Chemistry B, 2011, 115, 902-909.	1.2	18
164	Possibilities to increase the effectiveness of doxorubicin in cancer cells killing. Drug Metabolism Reviews, 2011, 43, 540-557.	1.5	62

#	Article	IF	Citations
165	Regioselective enzymatic acylation of complex natural products: expanding molecular diversity. Chemical Society Reviews, 2011, 40, 5321.	18.7	69
166	CaMKII-dependent SR Ca leak contributes to doxorubicin-induced impaired Ca handling in isolated cardiac myocytes. Journal of Molecular and Cellular Cardiology, 2011, 51, 749-759.	0.9	107
167	Doxorubicin pathways. Pharmacogenetics and Genomics, 2011, 21, 440-446.	0.7	1,167
168	Adriamycin nephropathy: A model of focal segmental glomerulosclerosis. Nephrology, 2011, 16, 30-38.	0.7	338
169	Superoxide dismutase (SOD) genes in Streptomyces peucetius: Effects of SODs on secondary metabolites production. Microbiological Research, 2011, 166, 391-402.	2.5	16
170	Anthracycline-GnRH derivative bioconjugates with different linkages: Synthesis, in vitro drug release and cytostatic effect. Journal of Controlled Release, 2011, 156, 170-178.	4.8	38
171	Tetrathiomolybdate induces doxorubicin sensitivity in resistant tumor cell lines. Gynecologic Oncology, 2011, 122, 183-189.	0.6	23
172	Fragment-based QSAR model toward the selection of versatile anti-sarcoma leads. European Journal of Medicinal Chemistry, 2011, 46, 5910-5916.	2.6	43
173	Cardioprotective effects of epigallocatechin-3-gallate against doxorubicin-induced cardiomyocyte injury. European Journal of Pharmacology, 2011, 652, 82-88.	1.7	55
174	Histone deacetylase inhibitors augment doxorubicin-induced DNA damage in cardiomyocytes. Cellular and Molecular Life Sciences, 2011, 68, 4101-4114.	2.4	20
175	Analysis of doxorubicin uptake in single human leukemia K562 cells using capillary electrophoresis coupled with laser-induced fluorescence detection. Analytical and Bioanalytical Chemistry, 2011, 401, 2143-2152.	1.9	26
176	Assay for determination of daunorubicin in cancer cells with multidrug resistance phenotype. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 1875-1880.	1.2	16
177	Neuronal Nitric Oxide Synthase is a Key Factor in Doxorubicin-Induced Toxicity to Rat-Isolated Cortical Neurons. Neurotoxicity Research, 2011, 19, 14-22.	1.3	14
178	Evaluation of the efficacy of radiation-modifying compounds using Î³H2AX as a molecular marker of DNA double-strand breaks. Genome Integrity, 2011, 2, 3.	1.0	25
179	Development of PEGylated doxorubicinâ€Łâ€[c(RGDfK)₂] conjugate for integrinâ€targeted cancer therapy. Polymers for Advanced Technologies, 2011, 22, 103-113.	1.6	22
180	Dietary red palm oil protects the heart against the cytotoxic effects of anthracycline. Cell Biochemistry and Function, 2011, 29, 356-364.	1.4	7
181	Cytotoxicity and topoisomerase I/II inhibition of glycosylated 2-phenyl-indoles, 2-phenyl-benzo[b]thiophenes and 2-phenyl-benzo[b]furans. Bioorganic and Medicinal Chemistry, 2011, 19, 603-612.	1.4	45
182	Stereo- and regioselective glycosylation of 4-deoxy-Îµ-rhodomycinone. Carbohydrate Research, 2011, 346, 858-862.	1.1	2

#	Article	IF	Citations
183	Concise and highly selective asymmetric synthesis of acosamine from sorbic acid. Tetrahedron Letters, 2011, 52, 2216-2220.	0.7	50
184	Doxorubicin variants for hematological malignancies. Nanomedicine, 2011, 6, 303-306.	1.7	11
185	Therapeutic targeting of B7-H1 in breast cancer. Expert Opinion on Therapeutic Targets, 2011, 15, 1211-1225.	1.5	36
186	Chemotherapy-Induced Weakness and Fatigue in Skeletal Muscle: The Role of Oxidative Stress. Antioxidants and Redox Signaling, 2011, 15, 2543-2563.	2.5	250
187	Use of Pattern Recognition Analysis to Identify Underlying Relationships of Doxorubicin Derivatives Optimized for Breast Cancer Treatment. ISRN Oncology, 2011, 2011, 1-6.	2.1	1
188	Chronic Doxorubicin Cardiotoxicity Modulates Cardiac Cytochrome P450-Mediated Arachidonic Acid Metabolism in Rats. Drug Metabolism and Disposition, 2012, 40, 2126-2135.	1.7	40
189	Trial watch. OncoImmunology, 2012, 1, 179-188.	2.1	104
190	Protective Effects of Berberine on Doxorubicin-Induced Hepatotoxicity in Mice. Biological and Pharmaceutical Bulletin, 2012, 35, 796-800.	0.6	76
191	Targeting Protein Tyrosine Kinase 6 Enhances Apoptosis of Colon Cancer Cells following DNA Damage. Molecular Cancer Therapeutics, 2012, 11, 2311-2320.	1.9	16
192	HPLC quantification of doxorubicin in plasma and tissues of rats treated with doxorubicin loaded poly(alkylcyanoacrylate) nanoparticles. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 887-888, 128-132.	1.2	58
193	Drugâ€“DNA binding thermodynamics: A comparative study of aristololactam-Î²-d-glucoside and daunomycin. Journal of Chemical Thermodynamics, 2012, 54, 421-428.	1.0	30
194	Cardiac phosphoproteome reveals cell signaling events involved in doxorubicin cardiotoxicity. Journal of Proteomics, 2012, 75, 4705-4716.	1.2	22
195	Inhibition of cell proliferation and migration by oxidative stress from ascorbate-driven juglone redox cycling in human bladder-derived T24 cells. Biochemical and Biophysical Research Communications, 2012, 421, 268-273.	1.0	25
196	Tetrathiomolybdate sensitizes ovarian cancer cells to anticancer drugs doxorubicin, fenretinide, 5-fluorouracil and mitomycin C. BMC Cancer, 2012, 12, 147.	1.1	30
197	Modulation of doxorubicin cytotoxicity by resveratrol in a human breast cancer cell line. Cancer Cell International, 2012, 12, 47.	1.8	59
198	Stability and iron coordination in DNA adducts of Anthracycline based anti-cancer drugs. Physical Chemistry Chemical Physics, 2012, 14, 12505.	1.3	10
199	Synthesis and Biological Characterization of Protease-Activated Prodrugs of Doxazolidine. Journal of Medicinal Chemistry, 2012, 55, 6595-6607.	2.9	30
200	Cardiotoxicity in childhood cancer survivors: strategies for prevention and management. Future Cardiology, 2012, 8, 647-670.	0.5	116

#	Article	IF	Citations
201	Risks and untoward toxicities of antibody-based immunoconjugates. Advanced Drug Delivery Reviews, 2012, 64, 1782-1799.	6.6	43
203	Anticancer mechanisms of action of two small amphipathic Î²2,2-amino acid derivatives derived from antimicrobial peptides. Biochimica Et Biophysica Acta - Biomembranes, 2012, 1818, 2917-2925.	1.4	37
204	Protection by low-dose Î³ radiation on doxorubicin-induced nephropathy in rats pretreated with curcumin, green tea, garlic or l-carnitine. Bulletin of Faculty of Pharmacy, Cairo University, 2012, 50, 133-140.	0.2	5
205	Doxorubicin-loaded silk films: Drug-silk interactions and inÂvivo performance in human orthotopic breast cancer. Biomaterials, 2012, 33, 8442-8450.	5.7	100
206	Understanding the binding of daunorubicin and doxorubicin to NADPH-dependent cytosolic reductases by computational methods. European Journal of Medicinal Chemistry, 2012, 56, 145-154.	2.6	12
207	Design, synthesis, cytocidal activity and estrogen receptor Î± affinity of doxorubicin conjugates at 16Î±-position of estrogen for site-specific treatment of estrogen receptor positive breast cancer. Steroids, 2012, 77, 1113-1122.	0.8	19
208	The clinically relevant pharmacogenomic changes in acute myelogenous leukemia. Pharmacogenomics, 2012, 13, 1257-1269.	0.6	36
209	Carbonyl reductase 1 expression influences daunorubicin metabolism in acute myeloid leukemia. European Journal of Clinical Pharmacology, 2012, 68, 1577-1586.	0.8	29
210	Mitochondrionopathy Phenotype in Doxorubicin-Treated Wistar Rats Depends on Treatment Protocol and Is Cardiac-Specific. PLoS ONE, 2012, 7, e38867.	1.1	31
211	Impact of Breast Cancer and Combination Chemotherapy on Oxidative Stress, Hepatic and Cardiac Markers. Journal of Breast Cancer, 2012, 15, 306.	0.8	29
212	Prognostic Values of Filamin-A Status for Topoisomerase II Poison Chemotherapy. International Journal of Biological Sciences, 2012, 8, 442-450.	2.6	8
213	Nanoparticles as delivery carriers for anticancer prodrugs. Expert Opinion on Drug Delivery, 2012, 9, 657-669.	2.4	50
214	Confirmation of drug delivery after liver chemoembolization: direct tissue doxorubicin measurement by UHPLCâ€MSâ€MS. Biomedical Chromatography, 2012, 26, 1529-1533.	0.8	11
215	Effects of Cyclic Lipodepsipeptide Structural Modulation on Stability, Antibacterial Activity, and Human Cell Toxicity. ChemMedChem, 2012, 7, 871-882.	1.6	52
216	Pretreatment and routine echocardiogram monitoring during chemotherapy for anthracyclineâ€induced cardiotoxicity rarely identifies significant cardiac dysfunction or alters treatment decisions. Cancer, 2012, 118, 1919-1924.	2.0	25
217	Synthesis and characterization of G5 PAMAM dendrimer containing daunorubicin for targeting cancer cells. Archives of Pharmacal Research, 2012, 35, 343-349.	2.7	25
218	Cytotoxic activity of some glycoconjugates including saponins and anthracyclines. Carbohydrate Research, 2012, 356, 295-298.	1.1	2
219	SnoaW/SnoaL2: A Different Two-Component Monooxygenase. Chemistry and Biology, 2012, 19, 549-551.	6.2	4

#	Article	IF	Citations
220	Photothermal-chemotherapy with doxorubicin-loaded hollow gold nanospheres: A platform for near-infrared light-trigged drug release. Journal of Controlled Release, 2012, 158, 319-328.	4.8	202
221	DoxilÂ® â€" The first FDA-approved nano-drug: Lessons learned. Journal of Controlled Release, 2012, 160, 117-134.	4.8	3,356
222	Manganese superoxide dismutase: beyond life and death. Amino Acids, 2012, 42, 139-158.	1.2	101
223	New dicoumarol sodium compound: crystal structure, theoretical study and tumoricidal activity against osteoblast cancer cells. Chemistry Central Journal, 2013, 7, 110.	2.6	9
224	Iodine and doxorubicin, a good combination for mammary cancer treatment: antineoplastic adjuvancy, chemoresistance inhibition, and cardioprotection. Molecular Cancer, 2013, 12, 45.	7.9	30
225	Octa-arginine-modified pegylated liposomal doxorubicin: An effective treatment strategy for non-small cell lung cancer. Cancer Letters, 2013, 335, 191-200.	3.2	79
226	The hydroxyl epimer of doxorubicin controls the rate of formation of cytotoxic anthracycline-DNA adducts. Cancer Chemotherapy and Pharmacology, 2013, 71, 809-816.	1.1	9
227	Validation of high-performance liqid chromatography method to determine epirubicin and its pharmacokinetics after intravenous bolus administration in rats. Journal of Pharmaceutical Investigation, 2013, 43, 243-249.	2.7	12
228	Mind the gap: A survey of how cancer drug carriers are susceptible to the gap between research and practice. Journal of Controlled Release, 2013, 172, 1045-1064.	4.8	193
229	Niche-based screening identifies small-molecule inhibitors of leukemia stem cells. Nature Chemical Biology, 2013, 9, 840-848.	3.9	103
230	Structure-Based DNA-Targeting Strategies with Small Molecule Ligands for Drug Discovery. Medicinal Research Reviews, 2013, 33, 1119-1173.	5.0	81
231	Complications of chemotherapy, a basic science update. Presse Medicale, 2013, 42, e352-e361.	0.8	30
232	Cardiovascular Toxicities of Cancer Chemotherapy. Seminars in Oncology, 2013, 40, 156-167.	0.8	37
233	OT-404, multi-targeted anti-cancer agent affecting tumor proliferation, chemo-resistance, and angiogenesis. Cancer Letters, 2013, 332, 55-62.	3.2	5
234	A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. European Journal of Pharmaceutical Sciences, 2013, 48, 416-427.	1.9	640
235	Surface functionalization of doxorubicin-loaded liposomes with octa-arginine for enhanced anticancer activity. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 84, 517-525.	2.0	72
236	NIR Megaâ€Stokes Fluorophores for Bioorthogonal Labeling and Energy Transfer Systemsâ€"An Efficient Quencher for Daunomycin. Chemistry - an Asian Journal, 2013, 8, 494-502.	1.7	14
237	Protective role of atorvastatin against doxorubicin-induced cardiotoxicity and testicular toxicity in mice. Journal of Physiology and Biochemistry, 2013, 69, 513-525.	1.3	28

#	Article	IF	Citations
238	Increasing the rate of heating: A potential therapeutic approach for achieving synergistic tumour killing in combined hyperthermia and chemotherapy. International Journal of Hyperthermia, 2013, 29, 145-155.	1.1	33
239	Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues. Cancer Chemotherapy and Pharmacology, 2013, 72, 127-138.	1.1	63
240	Natural Product Scaffolds in Cancer Therapy. , 2013, , 123-173.		1
241	Anthracycline nano-delivery systems to overcome multiple drug resistance: A comprehensive review. Nano Today, 2013, 8, 313-331.	6.2	117
242	Selfâ€Assembling Doxorubicin Silk Hydrogels for the Focal Treatment of Primary Breast Cancer. Advanced Functional Materials, 2013, 23, 58-65.	7.8	132
243	Both aerobic exercise and resveratrol supplementation attenuate doxorubicin-induced cardiac injury in mice. American Journal of Physiology - Endocrinology and Metabolism, 2013, 305, E243-E253.	1.8	105
244	Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nature Communications, 2013, 4, 1908.	5.8	310
245	An inulin and doxorubicin conjugate for improving cancer therapy. Journal of Drug Delivery Science and Technology, 2013, 23, 111-118.	1.4	25
246	Doxorubicin-Induced Cardiomyopathy and Benefits from Vitamin C. , 2013, , 187-198.		1
247	Radiation Sterilization of Anthracycline Antibiotics in Solid State. Scientific World Journal, The, 2013, 2013, 1-7.	0.8	10
248	The Influence of pH and Temperature on the Stability ofN-[(Piperidine)methylene]daunorubicin Hydrochloride and a Comparison of the Stability of Daunorubicin and Its Four New Amidine Derivatives in Aqueous Solutions. Scientific World Journal, The, 2014, 2014, 1-6.	0.8	3
249	The application of EDTA in drug delivery systems: doxorubicin liposomes loaded via NH4EDTA gradient. International Journal of Nanomedicine, 2014, 9, 3611.	3.3	24
250	Chemotherapeutic agents for the treatment of hepatocellular carcinoma: efficacy and mode of action. Oncology Reviews, 2014, 8, 246.	0.8	42
251	Strategy to enhance the therapeutic effect of doxorubicin in human hepatocellular carcinoma by selenocystine, a synergistic agent that regulates the ROS-mediated signaling. Oncotarget, 2014, 5, 2853-2863.	0.8	78
252	Anticancer efficacy and absorption, distribution, metabolism, and toxicity studies of Aspergiolide A in early drug development. Drug Design, Development and Therapy, 2014, 8, 1965.	2.0	19
253	Endurance exercise attenuates cardiotoxicity induced by androgen deprivation and doxorubicin. Canadian Journal of Physiology and Pharmacology, 2014, 92, 356-362.	0.7	10
254	Association of daunorubicin to a lipid nanoemulsion that binds to low-density lipoprotein receptors enhances the antitumour action and decreases the toxicity of the drug in melanoma-bearing mice. Journal of Pharmacy and Pharmacology, 2014, 66, 1698-1709.	1.2	16
255	Mitochondrial catastrophe during doxorubicinâ€induced cardiotoxicity: a review of the protective role of melatonin. Journal of Pineal Research, 2014, 57, 367-380.	3.4	134

#	Article	IF	Citations
256	N-3 polyunsaturated fatty acids decrease levels of doxorubicin-induced reactive oxygen species in cardiomyocytes -- involvement of uncoupling protein UCP2. Journal of Biomedical Science, 2014, 21, 101.	2.6	41
257	Novel stem-loop RNA and drug-bearing DNA hybrid nanostructures specific to LNCaP prostate carcinoma. Biomaterials Science, 2014, 2, 76-83.	2.6	4
258	Antimicrobial activity of saquayamycins produced by Streptomyces spp. PAL114 isolated from a Saharan soil. Journal De Mycologie Medicale, 2014, 24, e17-e23.	0.7	27
259	Novel cleavable cell-penetrating peptide-drug conjugates: synthesis and characterization. Journal of Peptide Science, 2014, 20, 323-333.	0.8	36
260	Optical tracking of drug release from porous silicon delivery vectors. IET Optoelectronics, 2014, 8, 113-116.	1.8	4
261	Reduced Graphene Oxide-Supported Gold Nanostars for Improved SERS Sensing and Drug Delivery. ACS Applied Materials & Interfaces, 2014, 6, 21798-21805.	4.0	168
262	Protection by Polyphenols Against Mitochondrial Damage and Cytotoxicity. , 2014, , 731-746.		2
263	Doxorubicin Encapsulation Investigated by Capillary Electrophoresis with Laser-Induced Fluorescence Detection. Chromatographia, 2014, 77, 1469-1476.	0.7	11
264	Structure-Based Engineering of Angucyclinone 6-Ketoreductases. Chemistry and Biology, 2014, 21, 1381-1391.	6.2	13
265	Selenorhodamine Photosensitizers for Photodynamic Therapy of P-Glycoprotein-Expressing Cancer Cells. Journal of Medicinal Chemistry, 2014, 57, 8622-8634.	2.9	53
266	AMP-activated Protein Kinase Î±2 and E2F1 Transcription Factor Mediate Doxorubicin-induced Cytotoxicity by Forming a Positive Signal Loop in Mouse Embryonic Fibroblasts and Non-carcinoma Cells. Journal of Biological Chemistry, 2014, 289, 4839-4852.	1.6	20
267	Mitochondrial Topoisomerase I (Top1mt) Is a Novel Limiting Factor of Doxorubicin Cardiotoxicity. Clinical Cancer Research, 2014, 20, 4873-4881.	3.2	102
268	Novel â€œBreath Figureâ€â€Based Synthetic PLGA Matrices for In Vitro Modeling of Mammary Morphogenesis and Assessing Chemotherapeutic Response. Advanced Healthcare Materials, 2014, 3, 703-713.	3.9	15
269	EPR: Evidence and fallacy. Journal of Controlled Release, 2014, 190, 451-464.	4.8	640
270	Cardiotoxicity of Antineoplastic Agents: What Is the Present and Future Role for Imaging?. Current Oncology Reports, 2014, 16, 396.	1.8	11
271	A co-delivery system based on paclitaxel grafted mPEG-b-PLG loaded with doxorubicin: Preparation, in vitro and in vivo evaluation. International Journal of Pharmaceutics, 2014, 471, 412-420.	2.6	38
272	Anticancer polymeric nanomedicine bearing synergistic drug combination is superior to a mixture of individually-conjugated drugs. Journal of Controlled Release, 2014, 187, 145-157.	4.8	98
273	Effects of adriamycin and candesartan on the collagen and elastin of the aorta in rats. Clinical Hypertension, 2014, 20, 8.	0.7	7

#	Article	IF	Citations
274	Association between DNA methylation and multidrug resistance in human glioma SHG-44 cells. Molecular Medicine Reports, 2015, 11, 43-52.	1.1	6
275	Antiprotozoal agents derived from natural soil and aquatic actinobacteria: Fighting one microbe with another. , 2015, , 457-478.		0
276	Is Metabolic Activation of Topoisomerase II Poisons Important In The Mechanism Of Cytotoxicity?. Journal of Drug Metabolism & Toxicology, 2015, 06, .	0.1	17
277	Recurrent pulmonary synovial sarcoma effectively treated with amrubicin: A case report. Experimental and Therapeutic Medicine, 2015, 9, 1947-1949.	0.8	3
278	In Vivo Protective Effects of Diosgenin against Doxorubicin-Induced Cardiotoxicity. Nutrients, 2015, 7, 4938-4954.	1.7	62
279	The Use of Anthracyclines for Therapy of CNS Tumors. Anti-Cancer Agents in Medicinal Chemistry, 2015, 15, 721-727.	0.9	24
280	Chemotherapy-Induced Cardiotoxicity: Overview of the Roles of Oxidative Stress. Oxidative Medicine and Cellular Longevity, 2015, 2015, 1-13.	1.9	193
281	Cobrotoxin fromNaja naja atraVenom Ameliorates Adriamycin Nephropathy in Rats. Evidence-based Complementary and Alternative Medicine, 2015, 2015, 1-15.	0.5	4
282	Ursolic acid benzaldehyde chalcone leads to inhibition of cell proliferation and arrests cycle in G1/G0 phase in ovarian cancer. Bangladesh Journal of Pharmacology, 2015, 10, 358.	0.1	0
283	p38Î´ MAPK phenotype. Anti-Cancer Drugs, 2015, 26, 46-55.	0.7	9
284	Myocardial MiR-30 downregulation triggered by doxorubicin drives alterations in Î²-adrenergic signaling and enhances apoptosis. Cell Death and Disease, 2015, 6, e1754-e1754.	2.7	98
285	Doxorubicin-Loaded Carborane-Conjugated Polymeric Nanoparticles as Delivery System for Combination Cancer Therapy. Biomacromolecules, 2015, 16, 3980-3988.	2.6	81
286	Polyploidy Formation in Doxorubicin-Treated Cancer Cells Can Favor Escape from Senescence. Neoplasia, 2015, 17, 882-893.	2.3	102
287	Targeted Prodrug Approaches for Hormone Refractory Prostate Cancer. Medicinal Research Reviews, 2015, 35, 554-585.	5.0	32
288	Resveratrol protects against doxorubicinâ€induced cardiotoxicity in aged hearts through the SIRT1â€USP7 axis. Journal of Physiology, 2015, 593, 1887-1899.	1.3	78
289	Protective effects of endothelin receptor A and B inhibitors against doxorubicin-induced cardiomyopathy. Biochemical Pharmacology, 2015, 94, 109-129.	2.0	23
290	Clinical Translation of Nanomedicine. Chemical Reviews, 2015, 115, 11147-11190.	23.0	619
291	Inherently Stealthy and Highly Tumor-Selective Gold Nanoraspberries for Photothermal Cancer Therapy. Scientific Reports, 2015, 5, 10311.	1.6	22

#	Article	IF	Citations
292	Probing the interactions of mitoxantrone with biomimetic membranes with electrochemical and spectroscopic techniques. Electrochimica Acta, 2015, 165, 430-442.	2.6	14
293	Human epidermal growth factor receptor-2 antibodies enhance theÂspecificity and anticancer activity of light-sensitive doxorubicin-labeled liposomes. Biomaterials, 2015, 57, 1-11.	5.7	43
294	The experimental model of nephrotic syndrome induced by Doxorubicin in rodents: an update. Inflammation Research, 2015, 64, 287-301.	1.6	34
295	Anti-malarials are anti-cancers and vice versa â€“ One arrow two sparrows. Acta Tropica, 2015, 149, 113-127.	0.9	23
296	Drug repurposing as an alternative for the treatment of recalcitrant bacterial infections. Frontiers in Microbiology, 2015, 6, 282.	1.5	143
297	Design and synthesis of novel hydroxyanthraquinone nitrogen mustard derivatives as potential anticancer agents via a bioisostere approach. European Journal of Medicinal Chemistry, 2015, 102, 303-309.	2.6	16
298	Divergent evolution of an atypical S -adenosyl- <scp>l</scp> -methionineâ€“dependent monooxygenase involved in anthracycline biosynthesis. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 9866-9871.	3.3	31
299	Melatonin: a protective role against doxorubicin-induced cardiotoxicity. Future Oncology, 2015, 11, 2003-2006.	1.1	11
300	Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis. European Journal of Cancer, 2015, 51, 2314-2320.	1.3	58
301	Smart IR780 Theranostic Nanocarrier for Tumor-Specific Therapy: Hyperthermia-Mediated Bubble-Generating and Folate-Targeted Liposomes. ACS Applied Materials & Interfaces, 2015, 7, 20556-20567.	4.0	98
302	Nuclear accumulation of anthracyclines in the endothelium studied by bimodal imaging: fluorescence and Raman microscopy. Analyst, The, 2015, 140, 2302-2310.	1.7	28
303	Isolation of doxorubicin from a bacterial culture using immobilised metal ion affinity chromatography. RSC Advances, 2015, 5, 46437-46442.	1.7	7
304	In vitrocytotoxicity of someNarcissusplants extracts. Natural Product Research, 2015, 29, 363-365.	1.0	2
305	Liposomal forms of anticancer agents beyond anthracyclines: present and future perspectives. Journal of Liposome Research, 2015, 25, 166-173.	1.5	5
306	Recent Advances in Developing Small Molecules Targeting Nucleic Acid. International Journal of Molecular Sciences, 2016, 17, 779.	1.8	53
307	Tetrahydroanthraquinone Derivative (Â±)-4-Deoxyaustrocortilutein Induces Cell Cycle Arrest and Apoptosis in Melanoma Cells via Upregulation of p21 and p53 and Downregulation of NF-kappaB. Journal of Cancer, 2016, 7, 555-568.	1.2	21
308	Mass spectrometric approaches for the identification of anthracycline analogs produced by actinobacteria. Journal of Mass Spectrometry, 2016, 51, 437-445.	0.7	10
309	Major Contributions towards Finding a Cure for Cancer through Chemotherapy: A Historical Review. Tumori, 2016, 102, 6-17.	0.6	20

#	Article	IF	Citations
310	Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come. Pharmacological Reviews, 2016, 68, 701-787.	7.1	537
311	A combined ligand- and structure-based approach for the identification of rilmenidine-derived compounds which synergize the antitumor effects of doxorubicin. Bioorganic and Medicinal Chemistry, 2016, 24, 3174-3183.	1.4	15
312	Characterization of Three Tailoring Enzymes in Dutomycin Biosynthesis and Generation of a Potent Antibacterial Analogue. ACS Chemical Biology, 2016, 11, 1992-2001.	1.6	15
313	Anticancer properties of new synthetic hybrid molecules combining naphtho[2,3-b]furan-4,9-dione or benzo[f]indole-4,9-dione motif with phosphonate subunit. European Journal of Medicinal Chemistry, 2016, 120, 51-63.	2.6	28
314	One-pot synthesis of 1,4-dihydroxy-2-((E)-1-hydroxy-4-phenylbut-3-enyl)anthracene-9,10-diones as novel shikonin analogs and evaluation of their antiproliferative activities. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2691-2694.	1.0	8
315	Thermo-Sensitive Liposome co-Loaded of Vincristine and Doxorubicin Based on Their Similar Physicochemical Properties had Synergism on Tumor Treatment. Pharmaceutical Research, 2016, 33, 1881-1898.	1.7	23
316	HIF inhibitors for ischemic retinopathies and cancers: options beyond anti-VEGF therapies. Angiogenesis, 2016, 19, 257-273.	3.7	22
317	Electrochemical Effects after Transarterial Chemoembolization in Combination with Percutaneous Irreversible Electroporation: Observations in an Acute Porcine Liver Model. Journal of Vascular and Interventional Radiology, 2016, 27, 913-921.e2.	0.2	11
318	Divergent non-heme iron enzymes in the nogalamycin biosynthetic pathway. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 5251-5256.	3.3	44
319	Sirt3 protects mitochondrial DNA damage and blocks the development of doxorubicin-induced cardiomyopathy in mice. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 310, H962-H972.	1.5	114
320	Complete Genome Sequence of a Novel Bacillus sp. VT 712 Strain Isolated from the Duodenum of a Patient with Intestinal Cancer. Genome Announcements, 2016, 4, .	0.8	1
321	Carbohydrate-based amphiphilic nano delivery systems for cancer therapy. Nanoscale, 2016, 8, 16091-16156.	2.8	145
322	Small-Molecule Procaspase-3 Activation Sensitizes Cancer to Treatment with Diverse Chemotherapeutics. ACS Central Science, 2016, 2, 545-559.	5.3	22
323	Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics. Drug Resistance Updates, 2016, 28, 65-81.	6.5	147
324	Effects of Adrenomedullin on Doxorubicin-Induced Cardiac Damage in Mice. Biological and Pharmaceutical Bulletin, 2016, 39, 737-746.	0.6	16
325	Fullerenol/doxorubicin nanocomposite mitigates acute oxidative stress and modulates apoptosis in myocardial tissue. Nanotechnology, 2016, 27, 485101.	1.3	14
326	Co-delivery of doxorubicin and quercetin via mPEGâ€“PLGA copolymer assembly for synergistic anti-tumor efficacy and reducing cardio-toxicity. Science Bulletin, 2016, 61, 1689-1698.	4.3	32
327	Mitoxantrone, More than Just Another Topoisomerase II Poison. Medicinal Research Reviews, 2016, 36, 248-299.	5.0	141

#	Article	IF	Citations
328	Cytotoxic, apoptotic, and sensitization properties of entâ€kauraneâ€type diterpenoids from Croton tonkinensis Gagnep on human liver cancer HepG2 and Hep3b cell lines. Fundamental and Clinical Pharmacology, 2016, 30, 137-146.	1.0	9
329	Characterization of Cell-Type-Specific Drug Transport and Resistance of Breast Cancers Using Tumor-Microenvironment-on-Chip. Molecular Pharmaceutics, 2016, 13, 2214-2223.	2.3	44
330	Spectroscopic studies of anthracyclines: Structural characterization and in vitro tracking. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2016, 169, 152-160.	2.0	30
331	Low Intensity Ultrasound Mediated Liposomal Doxorubicin Delivery Using Polymer Microbubbles. Molecular Pharmaceutics, 2016, 13, 55-64.	2.3	43
332	Review on the binding of anticancer drug doxorubicin with DNA and tRNA: Structural models and antitumor activity. Journal of Photochemistry and Photobiology B: Biology, 2016, 158, 274-279.	1.7	97
333	The novel anthraquinone derivative IMP1338 induces death of human cancer cells by p53-independent S and G2/M cell cycle arrest. Biomedicine and Pharmacotherapy, 2016, 79, 308-314.	2.5	16
334	Kinase-Dependent and -Independent Roles for PTK6 in Colon Cancer. Molecular Cancer Research, 2016, 14, 563-573.	1.5	19
335	Thymol and Carvacrol Prevent Doxorubicinâ€induced Cardiotoxicity by Abrogation of Oxidative Stress, Inflammation, and Apoptosis in Rats. Journal of Biochemical and Molecular Toxicology, 2016, 30, 37-44.	1.4	67
336	Doxorubicin toxicity changes myocardial energy metabolism in rats. Chemico-Biological Interactions, 2016, 244, 149-158.	1.7	43
337	Binding of the alkaloid aristololactam-Î²-D-glucoside and daunomycin to human hemoglobin: spectroscopy and calorimetry studies. Journal of Biomolecular Structure and Dynamics, 2016, 34, 800-813.	2.0	9
338	Chemical screening identifies the Î²-Carboline alkaloid harmine to be synergistically lethal with doxorubicin. Mechanisms of Ageing and Development, 2017, 161, 141-148.	2.2	20
339	In vivo comparative study of distinct polymeric architectures bearing a combination of paclitaxel and doxorubicin at a synergistic ratio. Journal of Controlled Release, 2017, 257, 118-131.	4.8	48
340	Protective effect of Coâ€enzyme Q10 On doxorubicinâ€induced cardiomyopathy of rat hearts. Environmental Toxicology, 2017, 32, 679-689.	2.1	45
341	Photothermal-triggered control of sub-cellular drug accumulation using doxorubicin-loaded single-walled carbon nanotubes for the effective killing of human breast cancer cells. Nanotechnology, 2017, 28, 125101.	1.3	37
342	Improved antitumor activity and reduced toxicity of doxorubicin encapsulated in poly(Îµ-caprolactone) nanoparticles in lung and breast cancer treatment: An in vitro and in vivo study. European Journal of Pharmaceutical Sciences, 2017, 102, 24-34.	1.9	49
343	The daunorubicin interplay with mimetic model membranes of cancer cells: A biophysical interpretation. Biochimica Et Biophysica Acta - Biomembranes, 2017, 1859, 941-948.	1.4	15
344	Overcoming drug resistance by cell-penetrating peptide-mediated delivery of a doxorubicin dimer with high DNA-binding affinity. European Journal of Medicinal Chemistry, 2017, 130, 336-345.	2.6	31
346	Targeting human telomeric G-quadruplex DNA with antitumour natural alkaloid aristololactam-Î²-D-glucoside and its comparison with daunomycin. Journal of Molecular Recognition, 2017, 30, e2639.	1.1	14

#	Article	IF	Citations
347	Overcoming the Road Blocks: Advancement of Block Copolymer Micelles for Cancer Therapy in the Clinic. Molecular Pharmaceutics, 2017, 14, 2503-2517.	2.3	71
348	Folate-targeted polymersomes loaded with both paclitaxel and doxorubicin for the combination chemotherapy of hepatocellular carcinoma. Acta Biomaterialia, 2017, 58, 399-412.	4.1	71
349	Clinical characteristics of doxorubicinâ€associated alopecia in 28 dogs. Veterinary Dermatology, 2017, 28, 207.	0.4	3
350	Daunorubicin and doxorubicin molecular interplay with 2D membrane models. Colloids and Surfaces B: Biointerfaces, 2017, 160, 610-618.	2.5	19
351	Cleavage Alters the Molecular Determinants of Protein Kinase C-Î´ Catalytic Activity. Molecular and Cellular Biology, 2017, 37, .	1.1	10
352	A review on the efficacy and toxicity of different doxorubicin nanoparticles for targeted therapy in metastatic breast cancer. Biomedicine and Pharmacotherapy, 2017, 95, 1209-1218.	2.5	222
353	Encapsulating Active Pharmaceutical Ingredients in Selfâ€Assembling Adamantanes with Short DNA Zippers. ChemMedChem, 2017, 12, 1759-1767.	1.6	6
354	Sequential Enyneâ€Metathesis/Dielsâ€“Alder Strategy: Rapid Access to Sugarâ€“Oxasteroidâ€“Quinone Hybrids. European Journal of Organic Chemistry, 2017, 2017, 5055-5065.	1.2	9
355	Iscador Qu inhibits doxorubicin-induced senescence of MCF7 cells. Scientific Reports, 2017, 7, 3763.	1.6	14
356	Pegylated liposomal formulation of doxorubicin overcomes drug resistance in a genetically engineered mouse model of breast cancer. Journal of Controlled Release, 2017, 261, 287-296.	4.8	70
357	Contribution of Organic Anion-Transporting Polypeptides 1A/1B to Doxorubicin Uptake and Clearance. Molecular Pharmacology, 2017, 91, 14-24.	1.0	33
358	Local delivery of doxorubicin through supramolecular peptide amphiphile nanofiber gels. Biomaterials Science, 2017, 5, 67-76.	2.6	57
359	A new cyano-substituted anthracycline metabolite from Streptomyces sp. HS-NF-1006. Journal of Antibiotics, 2017, 70, 219-221.	1.0	4
360	Proteomic analysis of the vitamin C effect on the doxorubicin cytotoxicity in the MCF-7 breast cancer cell line. Journal of Cancer Research and Clinical Oncology, 2017, 143, 35-42.	1.2	18
361	Rumex dentatus Inhibits Cell Proliferation, Arrests Cell Cycle, and Induces Apoptosis in MDA-MB-231 Cells through Suppression of the NF-ÎºB Pathway. Frontiers in Pharmacology, 2017, 8, 731.	1.6	14
362	Honokiol, an activator of Sirtuin-3 (SIRT3) preserves mitochondria and protects the heart from doxorubicin-induced cardiomyopathy in mice. Oncotarget, 2017, 8, 34082-34098.	0.8	137
363	Aldose reductase inhibitor, fidarestat prevents doxorubicin-induced endothelial cell death and dysfunction. Biochemical Pharmacology, 2018, 150, 181-190.	2.0	32
365	Preparation of Anthracyclines Liposomes for Tumor-Targeting Drug Delivery. Springer Reference Technik, 2018, , 1-21.	0.0	0

#	Article	IF	Citations
366	Statins in anthracycline-induced cardiotoxicity: Rac and Rho, and the heartbreakers. Cell Death and Disease, 2018, 8, e2564-e2564.	2.7	66
367	Doxorubicin targets multiple players: A new view of an old problem. Pharmacological Research, 2018, 127, 4-14.	3.1	123
368	Controlled release of Doxorubicin embedded in carboxymethyl chitosan nanofibers. Journal of the Textile Institute, 2018, 109, 178-185.	1.0	5
369	All-trans-retinoic acid ameliorates doxorubicin-induced cardiotoxicity: in vivo potential involvement of oxidative stress, inflammation, and apoptosis via caspase-3 and p53 down-expression. Naunyn-Schmiedeberg's Archives of Pharmacology, 2018, 391, 59-70.	1.4	43
370	Astaxanthin Ameliorates Doxorubicin-Induced Cognitive Impairment (Chemobrain) in Experimental Rat Model: Impact on Oxidative, Inflammatory, and Apoptotic Machineries. Molecular Neurobiology, 2018, 55, 5727-5740.	1.9	110
371	Masking Strategies for the Bioorthogonal Release of Anticancer Glycosides. , 2018, , 269-298.		0
372	Doxorubicin induces <scp>ZAK</scp>Î± overexpression with a subsequent enhancement of apoptosis and attenuation of survivability in human osteosarcoma cells. Environmental Toxicology, 2018, 33, 191-197.	2.1	3
373	Multivalency: Key Feature in Overcoming Drug Resistance with a Cleavable Cell-Penetrating Peptide-Doxorubicin Conjugate. International Journal of Peptide Research and Therapeutics, 2018, 24, 355-367.	0.9	2
374	Combined study on clastogenic, aneugenic and apoptotic properties of doxorubicin in human cells in vitro. Journal of Biological Research, 2018, 25, 17.	2.2	10
375	Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium. Frontiers in Pharmacology, 2018, 9, 1300.	1.6	602
376	Augmentation of NAD+ levels by enzymatic action of NAD(P)H quinone oxidoreductase 1 attenuates adriamycin-induced cardiac dysfunction in mice. Journal of Molecular and Cellular Cardiology, 2018, 124, 45-57.	0.9	22
377	Enhanced uptake and improved anti-tumor efficacy of doxorubicin loaded fibrin gel with liposomal apatinib in colorectal cancer. International Journal of Pharmaceutics, 2018, 552, 319-327.	2.6	9
378	Doxorubicin chemotherapy affects the intracellular and interstitial free amino acid pools in skeletal muscle. PLoS ONE, 2018, 13, e0195330.	1.1	4
379	Nanoformulations of doxorubicin: how far have we come and where do we go from here?. Nanotechnology, 2018, 29, 332002.	1.3	26
380	Melatonin improves cardiac and mitochondrial function during doxorubicin-induced cardiotoxicity: A possible role for peroxisome proliferator-activated receptor gamma coactivator 1-alpha and sirtuin activity?. Toxicology and Applied Pharmacology, 2018, 358, 86-101.	1.3	38
381	Thymoquinone Ameliorates Doxorubicin-Induced Cardiotoxicity in Swiss Albino Mice by Modulating Oxidative Damage and Cellular Inflammation. Cardiology Research and Practice, 2018, 2018, 1-6.	0.5	46
382	The role of nanoparticles in the improvement of systemic anticancer drug delivery. Therapeutic Delivery, 2018, 9, 527-545.	1.2	8
383	Ionic gradient liposomes: Recent advances in the stable entrapment and prolonged released of local anesthetics and anticancer drugs. Biomedicine and Pharmacotherapy, 2018, 107, 34-43.	2.5	20

#	Article	IF	Citations
384	Evaluation of selenium nanoparticles and doxorubicin effect against hepatocellular carcinoma rat model cytogenetic toxicity and DNA damage. Toxicology Reports, 2018, 5, 771-776.	1.6	26
385	Enhancement of oral bioavailability of doxorubicin through surface modified biodegradable polymeric nanoparticles. Chemistry Central Journal, 2018, 12, 65.	2.6	55
386	Enoxaparin attenuates doxorubicin induced cardiotoxicity in rats via interfering with oxidative stress, inflammation and apoptosis. BMC Pharmacology & Toxicology, 2018, 19, 3.	1.0	91
387	Doxorubicin-conjugated dexamethasone induced MCF-7 apoptosis without entering the nucleus and able to overcome MDR-1-induced resistance. Drug Design, Development and Therapy, 2018, Volume 12, 2361-2369.	2.0	25
388	Berberine as an Adjuvant and Sensitizer to Current Chemotherapy. , 2018, , 221-240.		0
389	Doxorubicin and ABT-199 Coencapsulated Nanocarriers for Targeted Delivery and Synergistic Treatment against Hepatocellular Carcinoma. Journal of Nanomaterials, 2019, 2019, 1-13.	1.5	0
390	One Pot and Metal-Free Approach to 3-(2-Hydroxybenzoyl)-1-aza-anthraquinones. Molecules, 2019, 24, 3017.	1.7	3
391	Synthesis and anticancer effects of conjugates of doxorubicin and unsaturated fatty acids (LNA and) Tj ETQq1 1 0.784314 rgBT /Over	1.1	23
392	An update on the mechanisms related to cell death and toxicity of doxorubicin and the protective role of nutrients. Food and Chemical Toxicology, 2019, 134, 110834.	1.8	67
393	Subcellular localization of the chemotherapeutic agent doxorubicin in renal epithelial cells and in tumor cells using correlative light and electron microscopy. Clinical Hemorheology and Microcirculation, 2019, 73, 157-167.	0.9	6
394	Cytotoxic Ru^{II}-p-cymene complexes of an anthraimidazoledione: halide dependent solution stability, reactivity and resistance to hypoxia deactivation. Dalton Transactions, 2019, 48, 7187-7197.	1.6	17
395	Self-Assembled Supramolecular Ribbon-Like Structures Complexed to Single Walled Carbon Nanotubes as Possible Anticancer Drug Delivery Systems. International Journal of Molecular Sciences, 2019, 20, 2064.	1.8	13
396	Polymeric Co-Delivery Systems in Cancer Treatment: An Overview on Component Drugsâ€™ Dosage Ratio Effect. Molecules, 2019, 24, 1035.	1.7	66
397	Time dependent response of daunorubicin on cytotoxicity, cell cycle and DNA repair in acute lymphoblastic leukaemia. BMC Cancer, 2019, 19, 179.	1.1	45
398	Pharmacokinetics and Pharmacodynamics Modeling and Simulation Systems to Support the Development and Regulation of Liposomal Drugs. Pharmaceutics, 2019, 11, 110.	2.0	49
399	Exosomal delivery of doxorubicin enables rapid cell entry and enhanced in vitro potency. PLoS ONE, 2019, 14, e0214545.	1.1	121
400	Doxorubicin-loaded red blood cells reduced cardiac toxicity and preserved anticancer activity. Drug Delivery, 2019, 26, 433-442.	2.5	32
401	The Proliferative and Apoptotic Landscape of Basal-like Breast Cancer. International Journal of Molecular Sciences, 2019, 20, 667.	1.8	19

#	Article	IF	Citations
402	Calpain-2 promotes MKP-1 expression protecting cardiomyocytes in both in vitro and in vivo mouse models of doxorubicin-induced cardiotoxicity. Archives of Toxicology, 2019, 93, 1051-1065.	1.9	16
403	Binding Parameters of Magnetite Nanoparticles Interaction with Anticancer Drug Doxorubicin. BioNanoScience, 2019, 9, 406-413.	1.5	6
404	Diltiazem potentiation of doxorubicin cytotoxicity and cellular uptake in human breast cancer cells. Breast Cancer Management, 2019, 8, BMT31.	0.2	6
405	Aclarubicin in subtoxic doses reduces doxorubicin cytotoxicity in human non-small cell lung adenocarcinoma (A549) and human hepatocellular carcinoma (HepG2) cells by decreasing DNA damage. Toxicology in Vitro, 2019, 55, 140-150.	1.1	6
406	Multiple actions of doxorubicin on the sphingolipid network revealed by flux analysis. Journal of Lipid Research, 2019, 60, 819-831.	2.0	20
407	Aspalathin ameliorates doxorubicin-induced oxidative stress in H9c2 cardiomyoblasts. Toxicology in Vitro, 2019, 55, 134-139.	1.1	24
408	Chemistry-oriented synthesis (ChOS) and target deconvolution on neuroprotective effect of a novel scaffold, oxaza spiroquinone. European Journal of Medicinal Chemistry, 2019, 163, 453-480.	2.6	15
409	Suppressing the growth of HL-60 acute myeloid leukemia cells by chitosan coated anthraquinone nanoparticles in vitro. International Journal of Polymeric Materials and Polymeric Biomaterials, 2019, 68, 819-826.	1.8	2
410	Metabolic and non-metabolic pathways that control cancer resistance to anthracyclines. Seminars in Cell and Developmental Biology, 2020, 98, 181-191.	2.3	51
411	In-Silico Repurposing of Anticancer Drug (5-FU) as an Antimicrobial Agent Against Methicillin-Resistant Staphylococcus aureus (MRSA). International Journal of Peptide Research and Therapeutics, 2020, 26, 2137-2145.	0.9	2
412	Recombinant Dual-target MDM2/MDMX Inhibitor Reverses Doxorubicin Resistance through Activation of the TAB1/TAK1/p38 MAPK Pathway in Wild-type p53 Multidrug-resistant Breast Cancer Cells. Journal of Cancer, 2020, 11, 25-40.	1.2	13
413	Doxorubicin inhibits PD-L1 expression by enhancing TTP-mediated decay of PD-L1 mRNA in cancer cells. Biochemical and Biophysical Research Communications, 2020, 522, 402-407.	1.0	16
414	Evolutionâ€guided engineering of nonâ€heme iron enzymes involved in nogalamycin biosynthesis. FEBS Journal, 2020, 287, 2998-3011.	2.2	2
415	Doxorubicin and Aclarubicin: Shuffling Anthracycline Glycans for Improved Anticancer Agents. Journal of Medicinal Chemistry, 2020, 63, 12814-12829.	2.9	27
416	Modification of carboxyl groups converts Î±-lactalbumin into an active molten globule state with membrane-perturbing activity and cytotoxicity. International Journal of Biological Macromolecules, 2020, 163, 1697-1706.	3.6	11
417	Thermodynamics and Kinetics of Drug-Target Binding by Molecular Simulation. Chemical Reviews, 2020, 120, 12788-12833.	23.0	126
418	Cardiotoxicity of doxorubicin-based cancer treatment: What is the protective cognition that phytochemicals provide us?. Pharmacological Research, 2020, 160, 105062.	3.1	24
419	Flavokawain B and Doxorubicin Work Synergistically to Impede the Propagation of Gastric Cancer Cells via ROS-Mediated Apoptosis and Autophagy Pathways. Cancers, 2020, 12, 2475.	1.7	24

#	Article	IF	Citations
420	Pathway Engineering of Anthracyclines: Blazing Trails in Natural Product Glycodiversification. Journal of Organic Chemistry, 2020, 85, 12012-12023.	1.7	7
421	Evaluation of the protective effects of Ganoderma applanatum against doxorubicin-induced toxicity in Daltonâ€™s Lymphoma Ascites (DLA) bearing mice. Drug and Chemical Toxicology, 2020, , 1-11.	1.2	3
422	Management of Cardiac Toxicity Induced by Chemotherapy. Journal of Clinical Medicine, 2020, 9, 2885.	1.0	24
423	Neurokinin receptor antagonism: a patent review (2014-present). Expert Opinion on Therapeutic Patents, 2020, 30, 527-539.	2.4	26
424	Utilizing Melatonin to Alleviate Side Effects of Chemotherapy: A Potentially Good Partner for Treating Cancer with Ageing. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-20.	1.9	29
425	Characterization and Therapeutic Effect of a pH Stimuli Responsive Polymeric Nanoformulation for Controlled Drug Release. Polymers, 2020, 12, 1265.	2.0	9
426	Synthesis and evaluation of new peptide-linked doxorubicin conjugates as prodrugs activated by prostate-specific antigen. Medicinal Chemistry Research, 2020, 29, 1280-1299.	1.1	6
427	The Rieske Oxygenase SnoT Catalyzes 2â€²â€²â€Hydroxylation of l â€Rhodosamine in Nogalamycin Biosynthesis. ChemBioChem, 2020, 21, 3062-3066.	1.3	3
428	Uncoupling DNA damage from chromatin damage to detoxify doxorubicin. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 15182-15192.	3.3	93
429	Drug Delivery Approaches for Doxorubicin in the Management of Cancers. Current Cancer Therapy Reviews, 2020, 16, 320-331.	0.2	13
430	Mitochondrial Determinants of Doxorubicin-Induced Cardiomyopathy. Circulation Research, 2020, 126, 926-941.	2.0	288
431	Role of aldoâ€keto reductase family 1 member B1 (AKR1B1) in the cancer process and its therapeutic potential. Journal of Cellular and Molecular Medicine, 2020, 24, 8890-8902.	1.6	48
432	Cancer therapy with iron oxide nanoparticles: Agents of thermal and immune therapies. Advanced Drug Delivery Reviews, 2020, 163-164, 65-83.	6.6	214
433	Dye binding assay reveals doxorubicin preference for DNA versus cardiolipin. Analytical Biochemistry, 2020, 594, 113617.	1.1	7
434	Current Approaches for Combination Therapy of Cancer: The Role of Immunogenic Cell Death. Cancers, 2020, 12, 1047.	1.7	95
435	Small molecules regulating reactive oxygen species homeostasis for cancer therapy. Medicinal Research Reviews, 2021, 41, 342-394.	5.0	107
436	Metabolic Aspects of Anthracycline Cardiotoxicity. Current Treatment Options in Oncology, 2021, 22, 18.	1.3	48
437	Tranilast prevents doxorubicin-induced myocardial hypertrophy and angiotensin II synthesis in rats. Life Sciences, 2021, 267, 118984.	2.0	11

#	Article	IF	Citations
438	Non-invasive transdermal delivery of chemotherapeutic molecules in vivo using superparamagnetic iron oxide nanoparticles. Cancer Nanotechnology, 2021, 12, .	1.9	17
439	Synthetic (N,N-Dimethyl)doxorubicin Glycosyl Diastereomers to Dissect Modes of Action of Anthracycline Anticancer Drugs. Journal of Organic Chemistry, 2021, 86, 5757-5770.	1.7	12
440	Gold nanoparticles as a drug delivery system for standard chemotherapeutics: A new lead for targeted pharmacological cancer treatments. Scientific African, 2021, 11, e00685.	0.7	48
441	Polymeric Nanocarriers: A Transformation in Doxorubicin Therapies. Materials, 2021, 14, 2135.	1.3	17
442	Magnetic Particles with Polymeric Shells Bearing Cholesterol Moieties Sensitize Breast Cancer Cells to Low Doses of Doxorubicin. International Journal of Molecular Sciences, 2021, 22, 4898.	1.8	7
443	DOKSORUBÄ°SÄ°N KARDÄ°YOTOKSÄ°SÄ°TESÄ°NÄ°N OLUÅžUMU VE Ã–NLENMESÄ°. Ìİzmir Democracy University Health Sciences Journal, 2021, 4, 1-15.	0.4	1
444	The Protective Effects of Borax on Doxorubicin Induced Cardiotoxicity In Rats. Bitlis Eren Ãœniversitesi Fen Bilimleri Dergisi, 0, , .	0.1	0
445	Streptomyces griseus KJ623766: A Natural Producer of Two Anthracycline Cytotoxic Metabolites Î²- and Î³-Rhodomycinone. Molecules, 2021, 26, 4009.	1.7	4
446	Potential Applications of Chitosan-Based Nanomaterials to Surpass the Gastrointestinal Physiological Obstacles and Enhance the Intestinal Drug Absorption. Pharmaceutics, 2021, 13, 887.	2.0	28
447	Nerolidol Attenuates Oxidative Stress, Inflammation, and Apoptosis by Modulating Nrf2/MAPK Signaling Pathways in Doxorubicin-Induced Acute Cardiotoxicity in Rats. Antioxidants, 2021, 10, 984.	2.2	35
448	Effects of neoadjuvant therapies on genetic regulation of targeted pathways in ER+Âprimary ductal breast carcinoma: A meta-analysis of microarray datasets. Saudi Pharmaceutical Journal, 2021, 29, 656-669.	1.2	2
449	Magnetic systems for cancer immunotherapy. Acta Pharmaceutica Sinica B, 2021, 11, 2172-2196.	5.7	40
450	Preparation of Anthracyclines Liposomes for Tumor-Targeting Drug Delivery. Biomaterial Engineering, 2021, , 365-384.	0.1	0
451	Solid Lipid Particles for Lung Metastasis Treatment. Pharmaceutics, 2021, 13, 93.	2.0	8
452	Anti-oxidant impact of Lisinopril and Enalapril against acute kidney injury induced by doxorubicin in male Wistar rats: involvement of kidney injury molecule-1. Heliyon, 2021, 7, e05985.	1.4	21
454	Anthracyclines. , 1997, , 113-136.		11
455	Efflux pump inhibitors as a promising adjunct therapy against drug resistant tuberculosis: a new strategy to revisit mycobacterial targets and repurpose old drugs. Expert Review of Anti-Infective Therapy, 2020, 18, 741-757.	2.0	29
456	An Improved HPLC Method for Therapeutic Drug Monitoring of Daunorubicin, Idarubicin, Doxorubicin, Epirubicin, and Their 13-Dihydro Metabolites in Human Plasma. Therapeutic Drug Monitoring, 1999, 21, 367.	1.0	68

#	Article	IF	Citations
457	Crystal structure and conformational analysis of doxorubicin nitrate. Acta Crystallographica Section E: Crystallographic Communications, 2018, 74, 400-405.	0.2	4
458	Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity.. Journal of Clinical Investigation, 1995, 95, 1595-1605.	3.9	73
459	Anthracyclines. , 2005, , .		2
460	Anthracyclines. Drugs and the Pharmaceutical Sciences, 1997, , 577-657.	0.1	10
461	tRNA Binding to Antitumor Drug Doxorubicin and Its Analogue. PLoS ONE, 2013, 8, e69248.	1.1	37
462	Anthraquinone G503 Induces Apoptosis in Gastric Cancer Cells through the Mitochondrial Pathway. PLoS ONE, 2014, 9, e108286.	1.1	16
463	Trichostatin A accentuates doxorubicin-induced hypertrophy in cardiac myocytes. Aging, 2010, 2, 659-668.	1.4	42
464	Mcl-1 regulates reactive oxygen species via NOX4 during chemotherapy-induced senescence. Oncotarget, 2017, 8, 28154-28168.	0.8	18
465	Efficient lytic induction of kaposi's sarcoma-associated herpesvirus (KSHV) by the anthracyclines. Oncotarget, 2014, 5, 8515-8527.	0.8	10
466	Hepatoprotective Role of Berberine on Doxorubicin Induced Hepatotoxicity - Involvement of Cyp. Current Drug Metabolism, 2020, 21, 541-547.	0.7	6
467	Creatine Alleviates Doxorubicin-Induced Liver Damage by Inhibiting Liver Fibrosis, Inflammation, Oxidative Stress, and Cellular Senescence. Nutrients, 2021, 13, 41.	1.7	36
468	Preventive role of carvedilol in adriamycin-induced cardiomyopathy. Indian Journal of Medical Research, 2016, 144, 725.	0.4	38
469	Practical consensus recommendations regarding the management of HER2 neu positive early breast cancer. South Asian Journal of Cancer, 2018, 07, 102-105.	0.2	3
470	Chitosan as possible inhibitory agents and delivery systems in leukemia. Cancer Cell International, 2021, 21, 544.	1.8	10
471	Drug Loading of Anthracycline Antibiotics on Carbon Dots Using Circular Dichroism Spectrometry. Analytical Chemistry, 2021, 93, 14773-14777.	3.2	5
475	Targeted Chemotherapy. , 2006, , 337-344.		0
477	Decreased Myocardial Tl-201 Uptake in Rats: Early Sign of Doxorubicin Induced Myocardial Damage and the Relation to Inflammation. Electronic Journal of General Medicine, 2010, 7, 43-49.	0.3	2
478	Topoisomerase II Inhibitors: Current Use and Prospects. Cancer Drug Discovery and Development, 2012, , 279-307.	0.2	1

#	Article	IF	Citations
479	Pharmacogenomics in Acute Myeloid Leukemia. , 2013, , 237-248.		2
480	Anthracycline-Induced Cardiotoxicity in Children: Pathophysiology and Prevention. Medical Radiology, 1995, , 175-180.	0.0	0
481	Mechanism of anthracycline cardiotoxicity and analysis of mechanisms of cardioprotective effect of drugs and compounds of various chemical groups. ScienceRise, 2016, 4, 42.	0.1	0
482	Chapter 12: Hollow Chitosanâ€'Alginate Multilayer Microcapsules as Drug Delivery Vehicle: Doxorubicin Loading and in vitro and in vivo Studies. , 2017, , 317-346.		0
483	Naringin protects rat lung against the doxorubicin-induced biochemical injury. MOJ Anatomy & Physiology, 2018, 5, .	0.2	0
484	Anthracyclines. WikiJournal of Medicine, 2018, 5, 1.	1.0	0
485	Ð•ÐÐ•ÐšÐ¢Ð˜ Ð•ÐÐ¢Ð•ÐÐžÐ¡ÐžÐÐ'Ð¦Ð†Ð‡ Ð¢Ð•ÐÐ†Ð›Ð"ÐÐÐ¡Ð¢Ð˜ÐœÐ£ ÐŸÐÐ˜ Ð¡Ð£Ð'Ð¥ÐÐžÐÐ†Ð§ÐÐ†Ð™ Ð'ÐžÐšÐ¤ÐÐžÐÐ£Ð		
486	Gallic acid inhibits celecoxib-induced mitochondrial permeability transition and reduces its toxicity in isolated cardiomyocytes and mitochondria. Human and Experimental Toxicology, 2021, 40, S530-S539.	1.1	4
487	Oxidative Modification Enzymes in Polyketide Biosynthetic Pathways. , 2020, , 479-505.		1
488	Reversal of doxorubicin resistance in lung cancer cells by neferine is explained by nuclear factor erythroid-derived 2-like 2 mediated lung resistance protein down regulation. , 2020, 3, 647-665.		3
489	Considerations for the Development of Novel Chemotherapies and Antibody Drug Conjugates in Phase I Trials. , 2020, , 185-198.		0
490	Label-free electrochemical detection of genetic damage induced by the interaction of a novel potential aminoanthraquinone-derived antitumor agent with DNA modified electrode. Sensors and Actuators B: Chemical, 2022, 352, 131036.	4.0	5
491	Chemopreventive effects of Panax notoginseng and its major constituents on SW480 human colorectal cancer cells. International Journal of Oncology, 2007, 31, 1149-56.	1.4	26
493	Trastuzumab-induced cardiac dysfunction: A 'dual-hit'. Experimental and Clinical Cardiology, 2011, 16, 70-4.	1.3	81
495	Sequential treatment with betulinic acid followed by 5-fluorouracil shows synergistic cytotoxic activity in ovarian cancer cells. International Journal of Clinical and Experimental Pathology, 2015, 8, 252-9.	0.5	5
496	A Simple and Sensitive HPLC Method for Fluorescence Quantitation of Doxorubicin in Micro-volume Plasma: Applications to Pharmacokinetic Studies in Rats. Iranian Journal of Pharmaceutical Research, 2015, 14, 33-42.	0.3	13
497	Effects of vitamin D on kidney histology and trpv1 channels in doxorubicin-induced nephropathy. International Journal of Clinical and Experimental Medicine, 2015, 8, 13548-55.	1.3	3
498	Sirt3 attenuates doxorubicin-induced cardiac hypertrophy and mitochondrial dysfunction via suppression of Bnip3. American Journal of Translational Research (discontinued), 2017, 9, 3360-3373.	0.0	18

#	Article	IF	Citations
499	Regulation and New Treatment Strategies in Breast Cancer. Journal of Life Sciences (Westlake Village,) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.8	2
500	Role of Oxygen and Nitrogen Radicals in the Mechanism of Anticancer Drug Cytotoxicity. Journal of Cancer Science & Therapy, 2020, 12, 10-18.	1.7	10
501	Biochemical studies on the protective effect of honey against doxorubicin-induced toxicity in BALB/C mice. International Journal of Health Sciences, 2020, 14, 31-37.	0.4	0
502	Reducing oxidative stress may be important for treating pirarubicinâ€induced cardiotoxicity with schisandrin B. Experimental and Therapeutic Medicine, 2021, 23, 68.	0.8	6
503	Interaction of Supramolecular Congo Red and Congo Red-Doxorubicin Complexes with Proteins for Drug Carrier Design. Pharmaceutics, 2021, 13, 2027.	2.0	6
504	Drug Repurposing for the Identification of Compounds with Anti-SARS-CoV-2 Capability via Multiple Targets. Pharmaceutics, 2022, 14, 176.	2.0	6
505	The cardioprotective effects of nanoâ€curcumin against doxorubicinâ€induced cardiotoxicity: A systematic review. BioFactors, 2022, 48, 597-610.	2.6	29
506	Anthracycline derivatives inhibit cardiac CYP2J2. Journal of Inorganic Biochemistry, 2022, 229, 111722.	1.5	4
507	Physiologically Based Pharmacokinetic Modelling and Simulation to Predict the Plasma Concentration Profile of Doxorubicin. Pharmaceutics, 2022, 14, 541.	2.0	1
508	In Vitro and In Vivo Cardioprotective Effects of Curcumin against Doxorubicin-Induced Cardiotoxicity: A Systematic Review. Journal of Oncology, 2022, 2022, 1-16.	0.6	11
509	Quantumâ€mechanical characterization of the doxorubicin molecule to improve its anticancer functions. MRS Advances, 2021, 6, 897-902.	0.5	4
510	Genome-Wide DNA Methylation Signatures Predict the Early Asymptomatic Doxorubicin-Induced Cardiotoxicity in Breast Cancer. Cancers, 2021, 13, 6291.	1.7	4
511	Optimised Electroporation for Loading of Extracellular Vesicles with Doxorubicin. Pharmaceutics, 2022, 14, 38.	2.0	39
512	Expression and Functional Contribution of Different Organic Cation Transporters to the Cellular Uptake of Doxorubicin into Human Breast Cancer and Cardiac Tissue. International Journal of Molecular Sciences, 2022, 23, 255.	1.8	11
513	Evaluation of Acetyl- and Butyrylcholinesterase Enzyme Inhibitory Activities and Cytotoxic Activities of Anthraquinone Derivatives. Journal of the Turkish Chemical Society, Section A: Chemistry, 2022, 9, 729-740.	0.4	1
514	Laccaseâ€TEMPO as an Efficient System for Doxorubicin Removal from Wastewaters. International Journal of Environmental Research and Public Health, 2022, 19, 6645.	1.2	5
515	Heterocyclic Anti-cancer Compounds Derived from Natural Sources with their Mechanism of Action. , 2022, , 1-56.		0
517	DOKSORUBÄ°SÄ°N Ä°LE OLUÅžTURULAN BÃ–BREK HASARINDA LERKANÄ°DÄ°PÄ°NÄ°N ANTÄ°OKSÄ°DAN VE ANTÄ°APOPTOTÄ°K ETKÄ° BCL-2/BAX/SÄ°T C/ CAS-3 YOLAÄžI ÃœZERÄ°NDEN ARAÅžTIRILMASI. SÃ¼leyman Demirel Ãœniversitesi TÄ±p FakÃ¼ltesi Dergisi, 2022, 29, 671-679.		1

#	Article	IF	Citations
518	Role of Nitric Oxide Synthases in Doxorubicin-Induced Cardiomyopathy. , 2023, , 127-145.		0
519	Effect of the Anticancer Drug Doxorubicin (Adriamycin) on Antioxidant Studies and Ultrastructural Investigation in the Liver, Kidney, and Heart Tissues of Male Rats. Biosciences, Biotechnology Research Asia, 2023, 20, 293-305.	0.2	0
520	Utilizing 505(b)(2) Regulatory Pathway for New Drug Applications: An Overview on the Advanced Formulation Approach and Challenges. , 0, , .		0